For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Juno Therapeutics Gmbh

USPTO Granted Patents = 77

% Expired Patents = 1.3

CIPO Patents = 1

EPO Patents = 37

Trademarks = 6

Forward Citations = 130

Loading Chart...

Loading Chart...

156 inventors (with patents filed for the assignee):

Mark J Gilbert (8 out of 21 patents)

He Li (8 out of 8 patents)

Calvin Chan (8 out of 8 patents)

4. Christopher Glen Ramsborg (7 out of 7 patents)

5. Steven M Shamah (7 out of 12 patents)

6. Pascal Beauchesne (7 out of 7 patents)

7. Csaba Pazmany (7 out of 11 patents)

8. Collin Hauskins (7 out of 7 patents)

9. Jui Dutta-Simmons (7 out of 7 patents)

10. Yan Chen (7 out of 53 patents)

11. Ryan P Larson (7 out of 7 patents)

12. Tina Albertson (6 out of 6 patents)

13. Lothar Germeroth (6 out of 10 patents)

14. Christian Stemberger (6 out of 9 patents)

15. Brian Christin (5 out of 5 patents)

Core Competencies:

Adoptive Cell Therapy

Engineered T Cells

Chimeric Antigen Receptors

Immunotherapy

Cell Culturing

Cell Processing

Antibodies

Tumor Burden

Genetic Engineering

Toxicity Assessment

Glycosylation

Immune Modulation

77 patents: Sort by Forward Citations

1. 12735727 - Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity (2026-09-15),

2. 12703734 - METHOD OF ASSESSING ACTIVITY OF RECOMBINANT ANTIGEN RECEPTORS (2026-08-11),

3. 12703733 - PROCESS FOR PRODUCING DONOR-BATCHED CELLS EXPRESSING A RECOMBINANT RECEPTOR (2026-08-11),

4. 12686728 - ANTI-IDIOTYPIC ANTIBODIES TO BCMA-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS (2026-07-21),

5. 12590882 - Threshold gating for flow cytometry methods (2026-03-31),

6. 12583904 - ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY (2026-03-24),

7. 12577285 - PROCESS FOR PRODUCING A COMPOSITION OF ENGINEERED T CELLS (2026-03-17),

8. 12570749 - ANTI-IDIOTYPIC ANTIBODIES TO GPRC5D-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS (2026-03-10),

9. 12553024 - SERUM-FREE MEDIA FORMULATION FOR CULTURING CELLS AND METHODS OF USE THEREOF (2026-02-17),

10. 12516099 - PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF (2026-01-06),

11. 12444491 - Machine learning methods for classifying cells (2025-10-14),

12. 12435120 - Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods (2025-10-07),

13. 12428486 - Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides (2025-09-30),

14. 12379375 - Methods for assessing cell surface glycosylation (2025-08-05),

15. 12366580 - Methods for mass spectrometry analysis of engineered cell compositions (2025-07-22),

Company Overview

Juno Therapeutics GmbH, based in Seattle, WA, specializes in the development of innovative adoptive cell therapies aimed at treating cancer. The company focuses on engineered T cells and chimeric antigen receptors (CARs) to enhance the immune system's ability to target and eliminate tumor cells. With expertise in immunotherapy, cell culturing, and processing, Juno is at the forefront of advancing therapeutic options that address significant tumor burdens, contributing to the evolving landscape of cancer treatment.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

77 Patents

#30 in Seattle, WA

#87 in Washington

#4,785 in US

#9,761 in the World

Seattle, WA, United States of America

Juno Therapeutics Gmbh

Forward Citations = 130

156 inventors:

Mark J Gilbert (8 out of 21 patents)

He Li (8 out of 8 patents)

Calvin Chan (8 out of 8 patents)

4. Christopher Glen Ramsborg (7 out of 7 patents)

5. Steven M Shamah (7 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Juno Therapeutics Gmbh. Retrieved from https://idiyas.com/company/juno-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…